Anthem (ANTX) Stock Price, News & Analysis

Company Overview

Anthem, Inc. is not currently associated with the Nasdaq ticker ANTX. The former Anthem, Inc. changed its name to Elevance Health, Inc. in 2022 and trades under the ticker ELV. ANTX is the ticker for AN2 Therapeutics, Inc., a separate biotechnology company.

AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly conditions for which existing therapies are limited. Its research has centered on novel anti-infective medicines and diseases affecting underserved patient populations.

The company’s lead investigational product has been epetraborole, an oral therapy studied for pulmonary disease caused by Mycobacterium avium complex, a difficult-to-treat bacterial infection. AN2 Therapeutics is based in the United States and has conducted clinical development activities internationally. Information provided here describes AN2 Therapeutics rather than Anthem or Elevance Health because of the ticker discrepancy.

Key Stats

• Today's Range: $4.26 to $4.67
• 50-Day Range: $4.40 to $6.28
• 52-Week Range: $1.00 to $7.19
• Volume: 442,134 shs
• Average Volume: 289,448 shs
• Market Capitalization: $166.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Anthem Stock Analysis - MarketRank™

Anthem scored higher than 34% of companies evaluated by MarketBeat, and ranked 630th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Anthem has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Anthem has a consensus price target of $9.00, representing about 104.5% upside from its current price of $4.40.

Amount of Analyst Coverage

Anthem has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Anthem is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Anthem is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Anthem has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.53% of the float of Anthem has been sold short.

Short Interest Ratio / Days to Cover

Anthem has a short interest ratio ("days to cover") of 9.54.

Change versus previous month

Short interest in Anthem has recently increased by 3.95%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Anthem does not currently pay a dividend.

Dividend Growth

Anthem does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Anthem this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Anthem insiders have sold 2,643.34% more of their company's stock than they have bought. Specifically, they have bought $11,602.00 in company stock and sold $318,282.00 in company stock.

Percentage Held by Insiders

22.61% of the stock of Anthem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.47% of the stock of Anthem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ANTX
• Previous Symbol: NASDAQ:ANTX
• CIK: 1156093
• Web: www.antheminc.com
• Phone: 650-331-9090
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Anthem: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +104.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.52%
• Return on Assets: -48.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.32
• Quick Ratio: 14.32

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 37,740,000
• Free Float: 29,204,000
• Market Cap: $166.06 million
• Optionable: Not Optionable
• Beta: -0.98